Smaller binding molecules such as nanobodies (~14 kDa) can detect HER2 avid metastases in patients on the day of injection [44], but it has been argued that the ideal molecular size would be below 10 kDa to allow efficient extravasation and tumor penetration [45]. This evidence concerns the gene ERBB2 and neoplasm.